These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 25476544)

  • 1. Ongoing challenges for pharmacotherapy for dyslipidemia.
    Pisaniello AD; Scherer DJ; Kataoka Y; Nicholls SJ
    Expert Opin Pharmacother; 2015 Feb; 16(3):347-56. PubMed ID: 25476544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].
    Bajnok L
    Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR; Knight M
    Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel strategies for managing dyslipidemia: treatment beyond statins.
    Ling H; Burns TL; Hilleman DE
    Postgrad Med; 2012 Nov; 124(6):43-54. PubMed ID: 23322138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Multimodal therapy of dyslipidemia].
    Stahn A; Hanefeld M
    Clin Res Cardiol Suppl; 2011 May; 6():10-6. PubMed ID: 22528173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery Approaches for Novel Dyslipidemia Drugs.
    Maqbool F; Safavi M; Bahadar H; Rahimifard M; Niaz K; Abdollahi M
    Curr Drug Discov Technol; 2015; 12(2):90-116. PubMed ID: 26135857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy in dyslipidemia: where are we now?
    Catapano AL; Farnier M; Foody JM; Toth PP; Tomassini JE; Brudi P; Tershakovec AM
    Atherosclerosis; 2014 Nov; 237(1):319-35. PubMed ID: 25299967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention.
    Page MM; Watts GF
    Expert Opin Emerg Drugs; 2015 Jun; 20(2):299-312. PubMed ID: 25861882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical significance of and treatment options for increased lipoprotein(a)].
    Zsíros N; Paragh G; Harangi M
    Orv Hetil; 2014 Apr; 155(16):607-14. PubMed ID: 24733102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future.
    Hajhosseiny R; Sabir I; Khavandi K; Wierzbicki AS
    Clin Pharmacol Ther; 2014 Jul; 96(1):64-73. PubMed ID: 24699033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-lowering treatment in peripheral artery disease.
    Katsiki N; Giannoukas AD; Athyros VG; Mikhailidis DP
    Curr Opin Pharmacol; 2018 Apr; 39():19-26. PubMed ID: 29413998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atherosclerosis stabilization with PCSK-9 inhibition: An evolving concept for cardiovascular prevention.
    Robinson JG; Heistad DD; Fox KA
    Atherosclerosis; 2015 Dec; 243(2):593-7. PubMed ID: 26545013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [News in lipid lowering treatment].
    Vrablík M; Češka R
    Vnitr Lek; 2014 Nov; 60(11):949-57. PubMed ID: 25600041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology.
    Page MM; Watts GF
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1505-15. PubMed ID: 26293511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid management in patients with chronic kidney disease.
    Ferro CJ; Mark PB; Kanbay M; Sarafidis P; Heine GH; Rossignol P; Massy ZA; Mallamaci F; Valdivielso JM; Malyszko J; Verhaar MC; Ekart R; Vanholder R; London G; Ortiz A; Zoccali C
    Nat Rev Nephrol; 2018 Dec; 14(12):727-749. PubMed ID: 30361677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.